{
    "clinical_study": {
        "@rank": "104202", 
        "arm_group": [
            {
                "arm_group_label": "600 mg N-acetylcysteine or placebo IV", 
                "arm_group_type": "Active Comparator", 
                "description": "600 mg N-acetylcysteine or placebo IV perfused over 15 minutes during the transplant procedure, prior to reperfusion,"
            }, 
            {
                "arm_group_label": "600 mg N-acetylcysteine or placebo NG", 
                "arm_group_type": "Active Comparator", 
                "description": "600 mg NAC or placebo administered via NG tube starting at 12 hrs  +  30 min post O.R. infusion,"
            }, 
            {
                "arm_group_label": "N-acetylcysteine or placebo q 12 hour", 
                "arm_group_type": "Active Comparator", 
                "description": "600 mg NAC or placebo administered via NG tube every 12 hrs + 30 min for 3 additional doses (at 24, 36 and 48 hrs post O.R. infusion). The total administration will be 3000 mg over a 48 hr period."
            }
        ], 
        "brief_summary": {
            "textblock": "Trial to test the effect of administering N-acetylcysteine on cytokines and markers of\n      oxidant stress and the incidence of acute renal failure post liver tranplant"
        }, 
        "brief_title": "Acute Renal Failure Post Liver Transplantation", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Renal Failure", 
        "condition_browse": {
            "mesh_term": [
                "Acute Kidney Injury", 
                "Renal Insufficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "1. To determine levels of pro-inflammatory cytokines and oxidative stress markers in liver\n           transplant patients during post-transplant period\n\n        2. To correlate changes in pro-inflammatory cytokines and markers of oxidative stress to\n           acute renal failure and acute rejection\n\n        3. To determine the impact of using N-acetylcysteine on cytokines and markers of oxidative\n           stress and the incidence of acute renal failure post liver transplantation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  First liver transplant\n\n          -  Normal renal function before transplantation [serum creatinine  \u2264 1.5 mg / dl]\n\n          -  No requirements for dialysis before transplantation\n\n          -  Age greater than 18 years\n\n        Exclusion Criteria:\n\n          -  Re-transplant\n\n          -  Renal dysfunction i.e. serum creatinine > 1.5 mg/dl\n\n          -  Need for dialysis before transplantation\n\n          -  Presence of Hepatorenal or Hepatopulmonary syndrome*\n\n          -  Combined liver and kidney transplant\n\n          -  Peptic ulcer disease\n\n          -  Pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "71 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01907061", 
            "org_study_id": "007-157"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "600 mg N-acetylcysteine or placebo IV", 
                    "600 mg N-acetylcysteine or placebo NG", 
                    "N-acetylcysteine or placebo q 12 hour"
                ], 
                "description": "drug will be administered via IV,NG", 
                "intervention_name": "N-acetylcysteine", 
                "intervention_type": "Drug", 
                "other_name": "NAC"
            }, 
            {
                "arm_group_label": [
                    "600 mg N-acetylcysteine or placebo IV", 
                    "600 mg N-acetylcysteine or placebo NG", 
                    "N-acetylcysteine or placebo q 12 hour"
                ], 
                "description": "placebo or NAC will be given", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo in place of NAC"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acetylcysteine", 
                "N-monoacetylcystine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "acute renal failure", 
            "post liver transplant"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75246"
                }, 
                "name": "Annette C. and Harold C. Simmons Tranplant Institute at Baylor Medical Center Dallas"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Acute Renal Failure Post Liver Transplantation: The Role of Cytokines and Oxidative Stress", 
        "overall_official": {
            "affiliation": "Baylor Health Care System", 
            "last_name": "Yousri M. Barri, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Cytokines in patients receiving N-acetylcysteine versus those receiving placebo during liver transplantation will be compared.", 
            "measure": "To determine levels of pro-inflammatory cytokines and oxidative stress markers in liver transplant patients during post-transplant period", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01907061"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "F2-isoprostanes levels in the two groups will be compared to evaluate the role in acute renal failure and acute rejection in patients recieving a liver transplant", 
                "measure": "To correlate changes in pro-inflammatory cytokines and markers of oxidative stress to acute renal failure and acute rejection", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "N-acetylcysteine or placebo will be given to patients recieving a liver tranplant cytokines and oxidative stress markers will be compared between the two groups to determine if N-acetylcysteine will impact acute renal failure post liver transplantation", 
                "measure": "iTo determine the impact of using N-acetylcysteine on cytokines and markers of oxidative stress and the incidence of acute renal failure post liver transplantation", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Baylor Research Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Baylor Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2007", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}